This report was recently updated on April 19 2024 with the latest and most recent
market numbers
Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market Size, Trends & Analysis - Forecasts to 2027 By Application (Non-invasive Prenatal Testing, Cancer Diagnostics, Others), By End-Use (Hospitals & Prenatal Clinics, Diagnostic Centers, Academic & Government Institutes, Biotechnology & Pharmaceutical Companies), By Region (North America, Asia Pacific, Central & South America, Europe, and the Middle East & Africa), End-User Landscape Analysis, Company Market Share Analysis, and Competitor Analysis
The global circulating cell-free DNA (ccfDNA) diagnostics market is projected to grow from USD 4.9 billion in 2022 to USD 13.1 billion in 2027 at a CAGR of 21.7% from 2022 to 2027.
Circulating cell-free DNA can be defined as fragments of DNA that are released in the plasma for critical and chronic diseases. Over the past years, ccfDNA or circulating DNA (ctDNA) as a non-invasive disease biomarker has gained traction as an attractive subject of research. The interest of the research community in clinical applications of ctDNA continues to witness an exponential increase, thereby driving its popularity as a potential target in a wide range of research areas.
Moreover, the ongoing developments and innovations in molecular technologies are advancing the investigation of cfDNA as a promising tool for the development of minimally invasive diagnostics. cfDNA -based diagnostics further improves informed clinical decision-making as well as patients' outcome. ctDNA has already proven its efficiency in prenatal medicine with the success of Natera’s Panorama prenatal test, Ariosa’s Harmony prenatal test, and Sequenom’s MaterniT21 Plus. The market players are now engaged in exploring its application in other unsaturated fields such as oncology, cardiovascular diseases, and others; to gain maximum profits through this market.
For instance, in May 2022, Lucene showcased the capability of ctDNA and circulating tumor RNA (ctRNA)-based liquid biopsy solution for lung cancer screening at the 2022 ASCO Annual Meeting. Such ongoing developments are anticipated to spur market growth at a lucrative rate during the forecast period.
However, further studies are required to elucidate a standardized approach for the analysis of these biomarkers in patients with cardiovascular diseases, neurological disorders, and other ailments. This creates opportunities for the new and emerging market players who are striving to gain market share in the space.
-diagnostics-market.png)
The COVID-19 pandemic has adversely affected the practice of prenatal care across the globe. Pregnant women must receive routine prenatal care for the detection of high-risk pregnancies as soon as feasible. However, due to the imposition of pandemic mandates, restricted access to medical services, and the risk of viral transmission, maternal prenatal care has been extremely challenging throughout the COVID-19 pandemic.
The suspension of all elective services to channel the workflow in the healthcare sector for management of COVID-19 patients coupled with restricted public transportation has interrupted prenatal care, thereby severely impacting the market growth. Moreover, the oncology field also witnessed a decline in cancer testing volume which indicates the negative impact of COVID-19 on the market.
The war between Russia and Ukraine has had a substantial impact on the global circulating cell-free DNA (ccfDNA) diagnostics market. Ukraine and Russia are facing production delays, a rise in transportation costs, and low sales due to the ongoing war. This also affects the other regions in Europe. Many countries trade with Russia and they are facing stockpiling and low demand due to increased prices.
Europe is home to several major market players as well as government research institutes. With the delay in the production of raw materials in Ukraine & Russia, several countries in Europe have reported supply shortages. This impacts the political relations in the international market. Many companies are temporarily shutting down their business in Russia, thereby affecting the overall market growth.
The non-invasive prenatal testing segment is estimated to account for the largest revenue share in the 2022 global circulating cell-free DNA (ccfDNA) diagnostics market. The success of cfDNA-based non-invasive tests has contributed to the dominance of this segment. Furthermore, expanding medical coverage for NIPTs is driving the segment.
For instance, in December 2020, Natera announced the extended coverage for NIPT across all pregnancies by the largest health plan in the U.S. With this policy change, Natera, along with other market players aimed to capitalize on the volume growth opportunity and improve test economics, thereby spurring the segment revenue.
The cancer diagnostics segment, on the other hand, is expected to grow the fastest from 2022-to 2027. Increasing investment in the development of liquid biopsy is the key driver of segment growth. For instance, in January 2021, Delfi Diagnostics, Inc. announced funding of USD 100 million for the development of liquid biopsy for the early detection of multiple cancers.
The hospitals & prenatal clinics segment is expected to capture the largest share in the global circulating cell-free DNA (ccfDNA) diagnostics market during the forecast period of 2022-2027. Growing awareness and popularity of non-invasive prenatal DNA screening among the population is spurred the revenue flow through this segment. Considering the advantages of NIPTs such as early risk detection of chromosomal anomalies including down syndrome and trisomy using NIPTs, the hospitals & prenatal clinics continue to be the largest end-user of the market.
Biotechnology & pharmaceutical companies are emerging as the fastest growing end-user of this market. The recent approval of companion diagnostics is the key driving force of this segment. For instance, in August 2020, the U.S. FDA approved the first liquid biopsy companion diagnostic- Guardant360 CDx both to deliver relevant insights into multiple solid tumor biomarkers and to help identify NSCLC patients who will be eligible for treatment using TAGRISSO.
-diagnostics-market.png)
The North American segment is expected to witness the largest share in the global circulating cell-free DNA (ccfDNA) diagnostics market during the forecast period of 2022-2027. With the presence of several domestic and global market players in the U.S., the North American segment is estimated to dominate the global circulating cell-free DNA (ccfDNA) diagnostics market.
Moreover, as one of the developed nations in the world, the United States is a hub for complex medical treatments for people around the world. The circulating cell-free DNA (ccfDNA) diagnostics market industry in the United States has been substantially strong for a few years due to the increasing demand for consumers in the healthcare domain, and it is estimated to grow further during the forecast period.
Asia-Pacific is expected to grow the fastest from 2022-to 2027. The Asia-Pacific region has been developing a huge infrastructure for the healthcare sector and a substantial number of medical innovations. This boosts the APAC circulating cell-free DNA (ccfDNA) diagnostics market.
Low manufacturing and operating cost, the presence of a large number of clinical subjects, and constantly developing healthcare infrastructure are some key reasons driving the Asian country markets such as China and India. Moreover, there is a substantial growth in R&D investments for exploring new and emerging areas such as liquid biopsy. These factors are bolstering the growth of the Asia market.
Hoffmann-La Roche, Natera Inc., Illumina Inc., Agena Bioscience, Paragon Genomics, Thermo Fisher Scientific, Bio-Rad Laboratories, Lucence Health, and Eurofins among others are some key players in the circulating cell-free DNA (ccfDNA) diagnostics market.
Please note: This is not an exhaustive list of companies profiled in the report.
The global market has witnessed several strategic alliances between companies that aimed at introducing novel products with added features. These strategies are not only driving the market growth but are also aimed at enhancing the company’s presence in the space.
Chapter 1 Research Methodology
1.1 Research Assumptions
1.2 Research Methodology
1.2.1 Estimates and Forecast Timeline
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GME’s Internal Database
1.3.3 Primary Research
1.3.4 Secondary Sources & Third-Party Perspectives
1.3.4.1 Company Information Sources
1.3.4.2 Secondary Data Sources
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Data Visualization
1.6 Data Validation & Publishing
1.7 Market Model
1.7.1 Model Details
1.7.1.1 Top-Down Approach
1.7.1.2 Bottom-Up Approach
1.8 Market Segmentation & Scope
1.9 Market Definition
Chapter 2 Executive Summary
2.1 Global Market Outlook
2.2 By End-Use Outlook
2.3 By Application Outlook
2.4 Regional Outlook
Chapter 3 Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market Trend Analysis
3.1. Market Introduction
3.2 Penetration & Growth Prospect Mapping
3.3 Impact of COVID-19 on the Circulating Cell-Free DNA (ccfDNA) Diagnostics Market
3.4 Metric Data based on the industry
3.5 Market Dynamic Analysis
3.5.1 Market Driver Analysis
3.5.2 Market Restraint Analysis
3.5.3 Industry Challenges
3.5.4 Industry Opportunities
3.6 Porter’s Five Analysis
3.6.1 Supplier Power
3.6.2 Buyer Power
3.6.3 Substitution Threat
3.6.4 Threat from New Entrant
3.7 Market Entry Strategies
Chapter 4 Circulating Cell-Free DNA (ccfDNA) Diagnostics Market: By Application Trend Analysis
5.1 By Application: Historic Data vs. Forecast Data Analysis, 2021 vs. 2027
5.2 Non-invasive Parental Testing
5.2.1 Market Estimates & Forecast Analysis of Non-invasive Parental Testing, By Region, 2019-2027 (USD Billion)
5.3 Cancer Diagnostics
5.3.1 Market Estimates & Forecast Analysis of Cancer Diagnostics Market Segment, By Region, 2019-2027 (USD Billion)
Chapter 5 Circulating Cell-Free DNA (ccfDNA) Diagnostics Market: By End-Use Trend Analysis
6.1 By End-Use: Historic Data vs. Forecast Data Analysis, 2022 vs. 2027
6.2 Hospitals & Prenatal Clinics
6.2.1 Market Estimates & Forecast Analysis of Hospitals & Prenatal Clinics Segment, By Region, 2019-2027 (USD Billion)
6.3 Diagnostic Centers
6.3.1 Market Estimates & Forecast Analysis of Diagnostic Centers Segment, By Region, 2019-2027 (USD Billion)
6.4 Academic & Government Institutes
6.4.1 Market Estimates & Forecast Analysis of Academic & Government Institutes Segment, By Region, 2019-2027 (USD Billion)
6.5 Biotechnology & Pharmaceutical Companies
6.5.1 Market Estimates & Forecast Analysis of Biotechnology & Pharmaceutical Companies Segment, By Region, 2019-2027 (USD Billion)
Chapter 6 Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Region
7.1 Regional Outlook
7.2 North America
7.2.1 Market Estimates & Forecast Analysis, By Country 2019-2027 (USD Billion)
7.2.2 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.2.3 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.2.4 U.S.
7.2.4.1 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.2.4.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.2.5 Canada
7.2.5.1 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.2.5.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.2.6 Mexico
7.2.6.1 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.2.6.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.3 Europe
7.3.1 Market Estimates & Forecast Analysis, By Country 2019-2027 (USD Billion)
7.3.2 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.3.3 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.3.4 Germany
7.3.4.1 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.3.4.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.3.5 UK
7.3.5.1 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.3.5.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.3.6 France
7.3.6.1 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.3.6.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.3.7 Russia
7.3.7.1 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.3.7.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.3.8 Italy
7.3.8.1 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.3.8.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.3.9 Spain
7.3.9.1 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.3.9.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.3.10 Rest of Europe
7.3.10.1 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.3.10.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.4 Asia Pacific
7.4.1 Market Estimates & Forecast Analysis, By Country 2019-2027 (USD Billion)
7.4.2 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.4.3 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.4.4 China
7.4.4.1 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.4.4.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.4.5 India
7.4.5.1 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.4.5.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.4.6 Japan
7.4.6.1 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.4.6.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.4.7 Australia
7.4.7.1 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.4.7.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.4.8 South Korea
7.4.8.1 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.4.8.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.3.9 Rest of Asia Pacific
7.3.9.1 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.3.9.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.5 Central & South America
7.5.1 Market Estimates & Forecast Analysis, By Country 2019-2027 (USD Billion)
7.5.2 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.5.3 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.5.4 Brazil
7.5.4.1 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.5.4.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.5.5 Rest of Central & South America
7.5.5.1 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.5.5.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.6 Middle East & Africa
7.6.1 Market Estimates & Forecast Analysis, By Country 2019-2027 (USD Billion)
7.6.2 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.6.3 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.6.4 Saudi Arabia
7.6.4.1 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.6.4.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.6.5 United Arab Emirates
7.6.5.1 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.6.5.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.6.6 South Africa
7.6.6.1 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.6.6.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
7.6.7 Rest of Middle East & Africa
7.6.7.1 Market Estimates & Forecast Analysis, By Application, 2019-2027 (USD Billion)
7.6.7.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2027 (USD Billion)
Chapter 7 Competitive Analysis
8.1 Key Global Players, Recent Developments & their Impact on the Industry
8.2 Four Quadrant Competitor Positioning Matrix
8.2.1 Key Innovators
8.2.2 Market Leaders
8.2.3 Emerging Players
8.2.4 Market Challengers
8.3 Vendor Landscape Analysis
8.4 End-User Landscape Analysis
8.5 Company Market Share Analysis, 2021
Chapter 8 Company Profile Analysis
9.1 Hoffman-La-Roche Ltd
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Strategic Initiatives
9.1.4 Product Benchmarking
9.2 Natera Inc.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Strategic Initiatives
9.2.4 Product Benchmarking
9.3 Illumina
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Strategic Initiatives
9.3.4 Product Benchmarking
9.4 Agena Bioscience
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Strategic Initiatives
9.4.4 Product Benchmarking
9.5 Paragon Genomics
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Strategic Initiatives
9.5.4 Product Benchmarking
9.6 Thermo Fisher Scientific
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Strategic Initiatives
9.6.4 Product Benchmarking
9.7 Bio-Rad Laboratories
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Strategic Initiatives
9.7.4 Product Benchmarking
9.8 Lucence Health
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Strategic Initiatives
9.8.4 Product Benchmarking
9.9 Eurofins
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Strategic Initiatives
9.9.4 Product Benchmarking
9.10 Other Companies
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Strategic Initiatives
9.10.4 Product Benchmarking
List of Tables
1 Technological Advancements in Circulating Cell-Free DNA (ccfDNA) Diagnostics Market
2 Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market: Key Market Drivers
3 Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market: Key Market Challenges
4 Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market: Key Market Opportunities
5 Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market: Key Market Restraints
6 Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market Estimates & Forecast Analysis, 2019-2027 (USD Billion)
7 Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Application, 2019-2027 (USD Billion)
8 Non-invasive Parental Testing: Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Region, 2019-2027 (USD Billion)
9 Cancer Diagnostics: Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Region, 2019-2027 (USD Billion)
10 Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By End-Use, 2019-2027 (USD Billion)
11 Hospitals & Prenatal Clinics: Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Region, 2019-2027 (USD Billion)
12 Diagnostic Centers: Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Region, 2019-2027 (USD Billion)
13 Academic & Government Institutes: Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Region, 2019-2027 (USD Billion)
14 Biotechnology & Pharmaceutical Companies: Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Region, 2019-2027 (USD Billion)
15 Regional Analysis: Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Region, 2019-2027 (USD Billion)
16 North America: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Application, 2019-2027 (USD Billion)
17 North America: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By End-Use, 2019-2027 (USD Billion)
18 North America: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Country, 2019-2027 (USD Billion)
19 U.S: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Application, 2019-2027 (USD Billion)
20 U.S: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By End-Use, 2019-2027 (USD Billion)
21 Canada: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Application, 2019-2027 (USD Billion)
22 Canada: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By End-Use, 2019-2027 (USD Billion)
23 Mexico: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Application, 2019-2027 (USD Billion)
24 Mexico: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By End-Use, 2019-2027 (USD Billion)
25 Europe: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Application, 2019-2027 (USD Billion)
26 Europe: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By End-Use, 2019-2027 (USD Billion)
27 Europe: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Country, 2019-2027 (USD Billion)
28 Germany: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Application, 2019-2027 (USD Billion)
29 Germany: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By End-Use, 2019-2027 (USD Billion)
30 UK: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Application, 2019-2027 (USD Billion)
31 UK: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By End-Use, 2019-2027 (USD Billion)
32 France: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Application, 2019-2027 (USD Billion)
33 France: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By End-Use, 2019-2027 (USD Billion)
34 Italy: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Application, 2019-2027 (USD Billion)
35 Italy: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By End-Use, 2019-2027 (USD Billion)
36 Spain: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Application, 2019-2027 (USD Billion)
37 Spain: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By End-Use, 2019-2027 (USD Billion)
38 Rest Of Europe: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Application, 2019-2027 (USD Billion)
39 Rest Of Europe: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By End-Use, 2019-2027 (USD Billion)
40 Asia Pacific: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Application, 2019-2027 (USD Billion)
41 Asia Pacific: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By End-Use, 2019-2027 (USD Billion)
42 Asia Pacific: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Country, 2019-2027 (USD Billion)
43 China: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Application, 2019-2027 (USD Billion)
44 China: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By End-Use, 2019-2027 (USD Billion)
45 India: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Application, 2019-2027 (USD Billion)
46 India: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By End-Use, 2019-2027 (USD Billion)
47 Japan: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Application, 2019-2027 (USD Billion)
48 Japan: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By End-Use, 2019-2027 (USD Billion)
49 South Korea: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Application, 2019-2027 (USD Billion)
50 South Korea: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By End-Use, 2019-2027 (USD Billion)
51 Middle East & Africa: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Application, 2019-2027 (USD Billion)
52 Middle East & Africa: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By End-Use, 2019-2027 (USD Billion)
53 Middle East & Africa: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Country, 2019-2027 (USD Billion)
54 Saudi Arabia: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Application, 2019-2027 (USD Billion)
55 Saudi Arabia: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By End-Use, 2019-2027 (USD Billion)
56 SOUTH AFRICA: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Application, 2019-2027 (USD Billion)
57 SOUTH AFRICA: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By End-Use, 2019-2027 (USD Billion)
58 Central & South America: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Application, 2019-2027 (USD Billion)
59 Central & South America: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By End-Use, 2019-2027 (USD Billion)
60 Central & South America: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Country, 2019-2027 (USD Billion)
61 Brazil: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By Application, 2019-2027 (USD Billion)
62 Brazil: Circulating Cell-Free DNA (ccfDNA) Diagnostics Market, By End-Use, 2019-2027 (USD Billion)
63 Hoffman-La-Roche: Products Offered
64 Natera Inc.: Products Offered
65 Illumina: Products Offered
66 Agena Bioscience: Products Offered
67 Paragon Genomics: Products Offered
68 Thermo Fisher Scientific: Products Offered
69 Eurofins: Products Offered
70 Bio-Rad Laboratories: Products Offered
71 Lucence Health: Products Offered
72 Other Companies: Products Offered
List of Figures
1. Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market Segmentation & Research Scope
2. Primary Research Partners and Local Informers
3. Primary Research Process
4. Primary Research Approaches
5. Primary Research Responses
6. Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market: Penetration & Growth Prospect Mapping
7. Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market: Value Chain Analysis
8. Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market Drivers
9. Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market Restraints
10. Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market Opportunities
11. Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market Challenges
12. Key Circulating Cell-Free DNA (ccfDNA) Diagnostics Market Manufacturer Analysis
13. Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market: Porter’s Five Forces Analysis
14. PESTLE Analysis & Impact Analysis
15. Hoffman-La-Roche: Company Snapshot
16. Hoffman-La-Roche: Swot Analysis
17. Natera Inc.: Company Snapshot
18. Natera Inc.: Swot Analysis
19. Illumina: Company Snapshot
20. Illumina: Swot Analysis
21. Agena Bioscience: Company Snapshot
22. Agena Bioscience: Swot Analysis
23. Paragon Genomics: Company Snapshot
24. Paragon Genomics: Swot Analysis
25. Eurofins: Company Snapshot
26. Eurofins: Swot Analysis
27. Bio-Rad Laboratories: Company Snapshot
28. Bio-Rad Laboratories: Swot Analysis
29. Lucence Health: Company Snapshot
30. Lucence Health: Swot Analysis
31. Thermo Fisher Scientific: Company Snapshot
32. Thermo Fisher Scientific: Swot Analysis
33. Other Companies: Company Snapshot
34. Other Companies: SWOT Analysis
The Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market has been studied from the year 2019 till 2027. However, the CAGR provided in the report is from the year 2022 to 2027. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Circulating Cell-Free DNA (ccfDNA) Diagnostics Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Frequently Asked Questions
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
